The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1449
August 18, 2014
View Complete Issue         Table of Contents 2019 
Two New Drugs for Skin and Skin Structure Infections
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Two New Drugs for Skin and Skin Structure Infections
August 18, 2014 (Issue: 1449)
The FDA has approved two new drugs for treatment of adults with acute bacterial skin and skin structure infections caused by susceptible gram-positive bacteria. Dalbavancin (Dalvance – Durata) is a long-acting intravenous (IV) lipoglycopeptide...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Two New Drugs for Skin and Skin Structure Infections
Article code: 1449a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.